Bulk Pharmaceutical API Sources for COARTEM

Bulk Pharmaceutical API Sources for COARTEM

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jb}AP@@HyivQQJJKJIRZN`mNmGrVjjjjjjjyaITQJduE@@
Ambinter		BB_NC-0820
R&D Chemicals		7501
Hangzhou Trylead Chemical Technology		TL8004521
NovoSeek		452191

Bulk Active Pharmaceutical Ingredient (API) Sources for COARTEM

Last updated: October 2, 2025

Introduction

Coartem, also known by its generic name artemether-lumefantrine, is a widely used combination therapy for treating uncomplicated malaria. Its efficacy hinges on the quality and reliability of its active pharmaceutical ingredients (APIs). Manufacturers sourcing bulk APIs for Coartem must navigate a complex landscape comprising regulatory standards, third-party suppliers, and regional manufacturing capabilities. This article provides a comprehensive overview of primary sources for artemether and lumefantrine APIs, emphasizing quality assurance, regulatory compliance, and strategic sourcing considerations.

---

Understanding Coartem API Composition

Coartem comprises two APIs:

1. Artemether: A derivative of artemisinin, sourced primarily from plant-based extraction or total synthesis.
2. Lumefantrine: A synthetic antimalarial agent synthesized via complex organic reactions.

Both APIs demand strict quality controls and adherence to pharmacopeial standards such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), or World Health Organization (WHO) guidelines.

---

Global API Manufacturing Landscape for Coartem

The sourcing of artemether and lumefantrine APIs involves multiple regions with distinct manufacturing capabilities:

• India: Emerging as a dominant global supplier, India offers a vast network of API producers compliant with WHO-GMP standards, making it a primary source for both APIs.
• China: Known for large-scale chemical synthesis, Chinese manufacturers provide competitive pricing and high manufacturing capacity but require rigorous quality verification.
• European and US Manufacturers: Offer high-quality API production with stringent regulatory oversight but often at premium prices and limited supply scale.

---

Key API Suppliers for Artimether

Indian Manufacturers

• Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
  Recognized for producing WHO-prequalified artemether APIs, supporting global health initiatives. Their operational GMP standards and robust quality management systems make them a preferred choice.

• Hetero Labs Ltd.
  A major Indian pharmaceutical producer with extensive experience in antimalarial APIs, compliant with international quality standards.

• Macleods Pharmaceuticals
  Offers GMP-certified artemether APIs suitable for global export, with established regulatory acceptance.

Chinese Manufacturers

• Ningbo Holike Chemical Co., Ltd.
  Produces artemether APIs with competitive pricing, adhering to chemical purity and stability standards but necessitating thorough vetting.

• Shandong Lianhua Pharmaceutical Co., Ltd.
  Known for extensive chemical synthesis expertise, providing artemether options for large-volume supply.

European/US Suppliers

• Xinhua Pharmaceuticals (Belgium)
  Offers high-quality APIs with comprehensive regulatory dossiers, suitable for markets demanding stringent compliance.

---

Key API Suppliers for Lumefantrine

Indian Manufacturers

• Farmangu Pharma
  Supplies lumefantrine conforming to WHO-GMP, with validated production processes.

• Macleods Pharmaceuticals
  Along with artemether, they manufacture lumefantrine, ensuring consistency and regulatory compliance.

Chinese Manufacturers

• Suzhou Xiangsheng Biopharmaceutical Co., Ltd.
  Provides lumefantrine APIs focusing on quality reproducibility, suitable for large-scale manufacturing.

• Shandong Lianhua Pharmaceutical Co., Ltd.
  Also supplies lumefantrine, backed by extensive synthesis expertise.

European/US Suppliers

• High-grade lumefantrine APIs are less common; mainly sourced from established European API manufacturers like Xinhua Pharmaceuticals, catering predominantly to regulated markets.

---

Quality Assurance and Regulatory Compliance

Sourcing APIs for Coartem demands meticulous validation:

• WHO Prequalification: Ensures APIs meet global standards; preferred for suppliers targeting procurement by UN agencies and NGOs.
• GMP Certification: Verifies adherence to Good Manufacturing Practices; essential for regulatory compliance across markets.
• Batch Consistency and Purity: APIs must demonstrate consistent potency, impurity profiles, and stability.

Due diligence involves auditing manufacturing sites, reviewing quality control documentation, and verifying regulatory submissions.

---

Strategic Sourcing Considerations

• Cost vs. Quality: Indian and Chinese manufacturers typically offer lower-cost APIs; however, stringent quality assessments are crucial.
• Supply Reliability: Long-term partnerships with established API producers minimize supply disruptions.
• Regulatory Acceptability: APIs from WHO-prequalified or GMP-certified facilities streamline global regulatory approvals, especially for products intended for public health programs.
• Regional Regulatory Challenges: Suppliers should consider regional registration hurdles and import tariffs influencing procurement strategies.

---

Emerging Trends and Future Outlook

• Increased Local Production: Growing capacity in Africa and Southeast Asia aims to reduce dependency on imports, critical for expanding access to affordable antimalarials.
• API Patents and Innovation: While artemether and lumefantrine APIs are largely off-patent, innovations in synthesis and formulation may influence sourcing preferences.
• Supply Chain Transparency: Due to past quality scandals, stakeholders are increasingly emphasizing traceability, certification, and verification audits.

---

Key Takeaways

• India and China dominate the bulk API supply market for artemether and lumefantrine, respectively, offering cost-effective and reliable options when compliant with quality standards.
• Quality assurance is paramount; sourcing from WHO-prequalified or GMP-certified manufacturers significantly reduces regulatory risks.
• Strategic partnerships with established suppliers facilitate stable supply chains, critical for malaria treatment programs.
• Due diligence through site audits, review of regulatory dossiers, and validation of manufacturing processes are essential for mitigating quality and compliance risks.
• Emerging regional manufacturing capacity and global initiatives aim to increase access to high-quality APIs, supporting large-scale malaria control efforts.

---

FAQs

1. What are the primary regulatory certifications to consider when sourcing APIs for Coartem?
Manufacturers should ideally supply APIs with WHO prequalification or GMP certification recognized internationally. These standards ensure compliance with safety, potency, and quality parameters.

2. How can I verify the quality of APIs from new suppliers?
Conduct comprehensive audits, review analytical data, certificates of analysis, and ensure batch-to-batch consistency. Partnering with analytical laboratories for independent testing enhances verification.

3. Are there regional differences in API quality for artemether and lumefantrine?
Yes. While Indian and Chinese manufacturers offer competitive pricing, European and US suppliers often adhere to more stringent regulatory frameworks. However, high-quality APIs are available from multiple regions, provided proper due diligence is performed.

4. What challenges exist in integrating APIs from China into global supply chains?
Regulatory acceptance may vary across markets. Import restrictions, certification requirements, and concerns over intellectual property can pose hurdles, emphasizing the need for thorough qualification processes.

5. How does regional manufacturing capacity impact global malaria treatment efforts?
Expanding regional API production reduces supply chain dependencies, lowers costs, and enhances local access to quality antimalarial medications, supporting global malaria eradication initiatives.

---

References

[1] WHO. (2020). Prequalification of medicines programme. World Health Organization.
[2] U.S. Pharmacopeia. (2022). USP General Chapter <1665> Active Pharmaceutical Ingredient.
[3] European Pharmacopoeia. (2022). Monographs on Artemether and Lumefantrine.
[4] Global Health Supply Chain Forum. (2021). Sourcing Strategies for Antimalarial APIs.
[5] Indian Pharmaceutical Congress. (2020). API Manufacturing Standards and Certification.